Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of EBV gp350-Ferritin Nanoparticle Vaccine in Healthy Adults
NCT04645147Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2022
- Primary completion
- Jul 2025
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Epstein-Barr virus gp350-ferritin vaccine in Epstein-Barr virus infection and infectious mononucleosis (IM) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Solicited Local Adverse Events, Number of Participants With Solicited Systemic Adverse Events and 3 more. Started Mar 2022; status: completed.
02
Drugs
Epstein-Barr virus gp350-ferritin vaccine
03
Conditions
Epstein-Barr virus infectioninfectious mononucleosis (IM)
Beyond the preview
Go deeper on NCT04645147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04645147.